Key facts
- ImmunoGenesis’s last known valuation is $142.0M (May 2025).
- It has raised $67.2M across 1 recorded rounds; the latest was Early Stage VC ($44.4M) in Mar 2024.
- Notable investors include Service Provider Capital, ADIT Ventures, Magnetar Capital, PEAK6 Strategic Capital, 3Spoke Capital — 13 tracked in total.
- ImmunoGenesis has filed 1 Form D with the SEC, most recently Apr 2024 ($44.4M sold to 88 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 1 rounds
- ·The complete investor list — 13 names
- ·Watchlist + deal alerts for ImmunoGenesis
Funding rounds
1 roundsAbout ImmunoGenesis
Developer of immuno-oncology therapeutics designed to create cold tumor treatments. The company specializes in immunotherapies to catalyze effective immune responses in immunologically cold cancers such as prostate, colorectal, and pancreatic cancer for the treatment of cancer patients, enabling healthcare professionals to get access to therapies that target key mechanisms of immune resistance.
- Sector
- Healthcare
- HQ
- Houston, TX, United States
- Founded
- 2019
- Employees
- 15
- Website
- immunogenesis.com/
- Ownership
- Privately Held (backing)
ImmunoGenesis doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in ImmunoGenesis shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on ImmunoGenesis in its N-PORT filings yet. We sweep new filings monthly.